Rivastigmine Transdermal Patch Simplified Adhesive Layer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal therapeutic systems (TTS) for rivastigmine, such as Exelon®, face issues with skin irritation and complex manufacturing processes due to their multi-layer structure, which increases costs and complexity.
Innovation Solution
A simplified TTS design featuring a backing layer and a rivastigmine-containing layer comprising a silicone acrylic hybrid polymer, eliminating the need for a rate-controlling membrane and reducing manufacturing complexity while maintaining effective drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a multi-layer structure (backing layer, rivastigmine-containing layer with acrylate polymers, and adhesive layer free of rivastigmine) is used to achieve effective drug delivery, then drug delivery properties are improved, but device complexity and manufacturing costs increase
Solution Approach 1:
The patent combines the adhesive layer and rivastigmine-containing layer into a single integrated layer. The adhesive layer comprises a mixture of acrylate polymer and silicone adhesive, with rivastigmine distributed throughout this combined layer. This eliminates the need for a separate adhesive layer free of rivastigmine, reducing structural complexity while maintaining effective drug delivery through the skin.
Solution Approach 2:
The adhesive layer in the invention serves multiple functions simultaneously: it provides adhesive properties to bond the patch to the skin, contains the rivastigmine drug for transdermal delivery, and acts as part of the drug reservoir. This multi-functionality reduces the number of separate components needed while achieving the same therapeutic effect.
2Ease of operation
If a multi-layer structure with two different adhesive layers is used to ensure proper skin adhesion, then adhesive performance is improved, but manufacturing complexity increases
Solution Approach 1:
The patent merges two separate adhesive layers into one unified adhesive layer that contains both acrylate polymer and silicone adhesive. This single layer provides the necessary skin adhesion properties without requiring complex multi-layer assembly processes, thereby simplifying manufacturing while maintaining effective skin bonding.
Solution Approach 2:
The adhesive layer is formulated as a composite material containing a mixture of acrylate polymer and silicone adhesive. This composite approach allows the single layer to exhibit the desirable properties of both materials, providing effective skin adhesion without the need for multiple separate adhesive layers.
3Manufacturing precision
If a rate-controlling membrane is added to achieve constant drug delivery, then delivery precision is improved, but device complexity and manufacturing costs increase
Solution Approach 1:
The patent achieves constant rivastigmine delivery by carefully controlling the composition and properties of the adhesive layer itself, rather than adding a separate rate-controlling membrane. By adjusting the polymer ratios, drug concentration, and layer thickness, the system provides controlled release through the adhesive layer's inherent properties, eliminating the need for additional membrane components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TTS provides constant and continuous rivastigmine delivery for at least 24 hours with reduced skin irritation and lower production costs, achieving comparable therapeutic plasma concentrations to existing systems.
Implementation Method 1
A transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine to the systemic circulation
Implementation Method 2
The TTS is designed to deliver approximately 2.3, 4.6, 6.7, 9.5, 13.3, or 17.4 mg of rivastigmine over a 24-hour period
Data Source
AI summary
The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of rivastigmine comprising a rivastigmine-containing layer structure, said rivastigmine-containing layer structure comprising: A) a backing layer; and B) a rivastigmine-containing layer.